|
US3311628A
(en)
*
|
1965-03-09 |
1967-03-28 |
Bristol Myers Co |
Derivatives of pyrrolo [2, 3-d] pyrimidine
|
|
CH592668A5
(e)
*
|
1973-10-02 |
1977-10-31 |
Delalande Sa |
|
|
EP0682027B1
(de)
*
|
1994-05-03 |
1997-10-15 |
Novartis AG |
Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
|
|
YU76100A
(sh)
|
1998-06-02 |
2003-12-31 |
Osi Pharmaceuticals Inc. |
Pirolo(2,3-d) pirimidin preparati i njihova primena
|
|
US6878716B1
(en)
|
1998-06-02 |
2005-04-12 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptor and uses thereof
|
|
US6686366B1
(en)
|
1998-06-02 |
2004-02-03 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
|
BR9911365A
(pt)
|
1998-06-19 |
2001-03-13 |
Pfizer Prod Inc |
Compostos pirrolo[2,3-d]pirimidina
|
|
US6680322B2
(en)
|
1999-12-02 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
|
US6664252B2
(en)
|
1999-12-02 |
2003-12-16 |
Osi Pharmaceuticals, Inc. |
4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
|
|
US7160890B2
(en)
|
1999-12-02 |
2007-01-09 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
|
EP1382339B1
(en)
|
1999-12-10 |
2007-12-05 |
Pfizer Products Inc. |
Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
|
|
US6680324B2
(en)
|
2000-12-01 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
|
US6673802B2
(en)
|
2000-12-01 |
2004-01-06 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
|
DE10148883A1
(de)
*
|
2001-10-04 |
2003-04-10 |
Merck Patent Gmbh |
Pyrimidinderivate
|
|
AU2002360436A1
(en)
|
2001-11-30 |
2003-06-17 |
Osi Pharmaceuticals, Inc. |
2-aryl pyrrologpyrimidines for a1 and a3 receptors
|
|
CN1620294A
(zh)
|
2001-12-20 |
2005-05-25 |
Osi药物公司 |
嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
|
|
CN101973998A
(zh)
|
2001-12-20 |
2011-02-16 |
Osi药物公司 |
吡咯并嘧啶A2b选择性拮抗剂化合物
|
|
NZ539901A
(en)
|
2002-11-26 |
2007-09-28 |
Pfizer Prod Inc |
Method of treatment of transplant rejection
|
|
US20070208053A1
(en)
*
|
2006-01-19 |
2007-09-06 |
Arnold Lee D |
Fused heterobicyclic kinase inhibitors
|
|
JP4884570B2
(ja)
|
2008-08-20 |
2012-02-29 |
ファイザー・インク |
ピロロ[2,3−d]ピリミジン化合物
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
WO2026050970A1
(zh)
*
|
2024-09-05 |
2026-03-12 |
甫康(上海)健康科技有限责任公司 |
一种用于吡咯并[2,3-d]嘧啶衍生物的制备方法和新颖中间体
|